Results 201 to 210 of about 6,459 (257)

Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review

Journal of Diabetes, Volume 18, Issue 7, July 2026.
RCTs of incretin‐based treatment show effective weight loss and glycemic benefit, as well as improved CV outcomes. There is, however, uncertainty as to whether the RCTs translate to real‐world outcomes. This narrative review suggests real‐world outcomes are comparable to RCTs after accounting for submaximal dosing and high discontinuation rates ...
Zachary Bloomgarden
wiley   +1 more source

GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists. [PDF]

Diabetes Metab Syndr Obes
Abid M, Sheikh KS, Ahmad MS, Jiang H.
europepmc   +1 more source

Association of GLP‐1 Receptor Agonist Prescriptions and Alcohol Consumption in the National Institutes of Health's All of Us Cohort

Alcohol, Clinical and Experimental Research, Volume 50, Issue 7, July 2026.
This cohort study examined whether GLP‐1 receptor agonist prescriptions are associated with alcohol use among NIH All of Us participants. Those with current GLP‐1RA prescriptions showed modestly lower AUDIT‐C scores compared to those with future prescriptions. GLP‐1RAs may reduce alcohol consumption by reducing drinking frequency.
Benjamin Tyndall, Angela Gasdaska, M. Daniel Brannock, Ed Preble, Melissa McPheeters, Laura Marcial, Ariba Huda, Josephine Egan, Tamara R. Litwin, Jennifer Adjemian, Chandan Sastry, Mehdi Farokhnia, Lorenzo Leggio   +12 more
wiley   +1 more source

Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1. [PDF]

J Endocrinol Invest
Sattar N, Tchang BG, Vincent RP, Wang H, Murphy M, Dunn JP, Dimitriadis GK, Fraseur Brumm J.   +7 more
europepmc   +1 more source

Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5761-5766, July 2026.
ABSTRACT Aims To characterize the cardiometabolic profiles of oral and subcutaneous glucagon‐like peptide‐1 (GLP‐1) receptor mono‐agonists in adults with overweight or obesity, with or without type 2 diabetes (T2D), using network meta‐analysis (NMA).
Ying Lu, Jiajie Chen, Yuqing Guo, Hao Ding, Yu‐Lun Liu, Michelle A. Van Name, Mona Sharifi, Yuan Lu, Yong Chen   +8 more
wiley   +1 more source

Hypercalcemia Induced by Tirzepatide and Calcium Supplementation: A Case Report. [PDF]

Cureus
Nguyen E, Kawamura M, Munoz I, Ahn G.
europepmc   +1 more source

Semaglutide 2.4 mg Cardiometabolic Long‐Term Effects in Patients With Obesity or Overweight in a Real‐World Setting: A Retrospective Cohort Study in the United States (SMILE)

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6121-6130, July 2026.
ABSTRACT Aims To evaluate the real‐world associations between semaglutide 2.4 mg and cardiometabolic comorbidities, biomarkers and cardiovascular risk among adults with overweight or obesity. Methods This retrospective cohort study used US claims data and laboratory measurements from the Komodo Research Database (2016–2024). Adults with obesity or with
Aleksandrina Ruseva, Wojciech Michalak, Matthew Bassan, Ella Xiaoyan Du, Anthony Fabricatore, Bríain Ó Hartaigh, Theo Man, Ramya Ramasubramanian, Pangsibo Shen, Jinlin Song, Zhenxiang Zhao, Francisco Lopez‐Jimenez   +11 more
wiley   +1 more source

Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6. [PDF]

Diabetes Ther
Bajaj HS, Billings LK, Sharma P, Levine JA, Rodriguez A, Patel H.   +5 more
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5915-5925, July 2026.
ABSTRACT Aims Petrelintide is a long‐acting amylin analogue in development for weight management. The safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide were evaluated in single ascending dose (SAD) and multiple ascending dose (MAD) trials. Materials and Methods Both trials were randomized, placebo‐controlled, and double‐blind.
Minna Brændholt Olsen, Jon Griffin, Ulrike Hövelmann, Stanislava Macura, Berith Fredsted Hagen, Dan Hesse, Tim Heise   +6 more
wiley   +1 more source

Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real-World Evidence. [PDF]

Endocrinol Diabetes Metab
Acucella GA, Caponio D.
europepmc   +1 more source